ECSP21060868A - 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresión - Google Patents

5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresión

Info

Publication number
ECSP21060868A
ECSP21060868A ECSENADI202160868A ECDI202160868A ECSP21060868A EC SP21060868 A ECSP21060868 A EC SP21060868A EC SENADI202160868 A ECSENADI202160868 A EC SENADI202160868A EC DI202160868 A ECDI202160868 A EC DI202160868A EC SP21060868 A ECSP21060868 A EC SP21060868A
Authority
EC
Ecuador
Prior art keywords
disorder
dimethyltryptamine
dmt
meo
depression
Prior art date
Application number
ECSENADI202160868A
Other languages
English (en)
Inventor
Theis Terwey
Original Assignee
Gh Res Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gh Res Ireland Limited filed Critical Gh Res Ireland Limited
Publication of ECSP21060868A publication Critical patent/ECSP21060868A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan composiciones para su uso en el tratamiento de un paciente que padece un trastorno mental en particular trastorno depresivo mayor, trastorno depresivo persistente, trastorno de ansiedad, trastorno de estrés postraumático, trastorno dismórfico corporal, trastorno obsesivo compulsivo, trastorno alimentario y abuso de sustancias psicoactivas. Se proporcionan además regímenes de dosificación para tratar estos trastornos.
ECSENADI202160868A 2019-02-22 2021-08-17 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresión ECSP21060868A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19158774 2019-02-22

Publications (1)

Publication Number Publication Date
ECSP21060868A true ECSP21060868A (es) 2021-11-30

Family

ID=65529503

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202160868A ECSP21060868A (es) 2019-02-22 2021-08-17 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresión

Country Status (23)

Country Link
US (1) US20220071958A1 (es)
EP (3) EP4349407A2 (es)
JP (1) JP2022521337A (es)
KR (1) KR20210154966A (es)
CN (1) CN114555078A (es)
AU (1) AU2020225410A1 (es)
BR (1) BR112021016153A2 (es)
CA (1) CA3130406A1 (es)
CL (1) CL2021002174A1 (es)
CO (1) CO2021010882A2 (es)
CR (1) CR20210437A (es)
DK (1) DK3927337T3 (es)
DO (1) DOP2021000176A (es)
EA (1) EA202192318A1 (es)
EC (1) ECSP21060868A (es)
FI (1) FI3927337T3 (es)
IL (1) IL285537A (es)
MA (1) MA55021B1 (es)
MX (1) MX2021009941A (es)
NI (1) NI202100080A (es)
PE (1) PE20220015A1 (es)
PT (1) PT3927337T (es)
WO (1) WO2020169850A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
EP3753923A1 (en) * 2019-06-19 2020-12-23 GH Research Limited Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent
JP7423131B2 (ja) 2019-11-07 2024-01-29 サイビン ユーケー リミテッド 化合物
EP3868364A1 (en) 2020-02-24 2021-08-25 GH Research Limited Aerosol comprising 5-methoxy-n,n-dimethyltryptamine
MX2022014605A (es) 2020-05-19 2022-12-16 Cybin Irl Ltd Derivados de triptamina deuterada y metodos de uso.
US20210378969A1 (en) 2020-06-02 2021-12-09 Small Pharma Ltd. Therapeutic solid dosage forms
US11773062B2 (en) 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
AU2021289147A1 (en) 2020-06-12 2023-02-02 Beckley Psytech Limited Composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine
CA3188263A1 (en) * 2020-08-05 2022-02-10 Matthias Emanuel LIECHTI Intravenous dmt administration method for dmt-assisted psychotherapy
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
EP4138818A1 (en) 2020-08-28 2023-03-01 Small Pharma Ltd Injectable formulation
KR20230079351A (ko) * 2020-10-02 2023-06-07 사이빈 아이알엘 리미티드 흡입에 의한 심리치료제(psychedelic) 약물의 전달을 위한 방법 및 이 방법을 수행하기 위한 시스템
CN112138028A (zh) * 2020-10-10 2020-12-29 南京中医药大学 蟾蜍色胺类物质在制备抗抑郁药物中的应用
WO2022082058A1 (en) * 2020-10-16 2022-04-21 Eleusis Therapeutics Us, Inc. Method of treatment by tryptamine alkaloids
WO2022117640A1 (en) * 2020-12-01 2022-06-09 Small Pharma Ltd Inhalable formulations
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
CA3113414A1 (en) * 2021-03-29 2022-09-29 Mind Cure Health Inc. Psychedelics protocol computer systems and methods
US11602521B2 (en) 2021-04-26 2023-03-14 ATAI Life Sciences AG N,N-dimethyltryptamine compositions and methods
WO2022235927A1 (en) * 2021-05-05 2022-11-10 Gilgamesh Pharmaceuticals, Inc. Novel tryptamines and methods of treating mood disorders
US11697638B2 (en) 2021-09-08 2023-07-11 Small Pharma Ltd 5-methoxy-N,N-dimethyltryptamine crystalline forms
EP4159201A1 (en) * 2021-09-30 2023-04-05 Biomind Labs Inc Encapsulated microparticles and nanoparticles of dimethyltriptamines
AU2022393234A1 (en) * 2021-11-18 2024-06-06 Cybin Uk Ltd Injectable and inhalable formulations
CA3238440A1 (en) 2021-12-30 2023-07-06 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
WO2023186826A1 (en) 2022-03-27 2023-10-05 GH Research Ireland Limited 5-meo-dmt for use in the treatment of postpartum depression
WO2023186834A1 (en) 2022-03-27 2023-10-05 GH Research Ireland Limited Crystalline hydrobromide salt of 5-meo-dmt
WO2023186831A1 (en) 2022-03-27 2023-10-05 GH Research Ireland Limited 5-methoxy-n.n-dimethyltryptamine for the treatment of psychomotor retardation
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19803376C1 (de) 1998-01-29 1999-10-14 Markus Storz Inhalator zur Erzeugung von aroma- und/oder wirkstoffhaltigen Dämpfen aus Pflanzenmaterial und/oder Flüssigkeiten
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
EP1625333A1 (en) 2003-05-21 2006-02-15 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
DE502006008441D1 (de) 2006-08-01 2011-01-13 Stobi Gmbh & Co Kg Ventilballon für Inhalatoren
CN103816150A (zh) * 2014-03-14 2014-05-28 兰州理工大学 山蚂蝗生物碱单体成分的用途
US20200147038A1 (en) * 2017-04-20 2020-05-14 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
MA50786A (fr) * 2017-10-26 2022-04-27 Blumentech S L Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques

Also Published As

Publication number Publication date
CR20210437A (es) 2021-11-02
IL285537A (en) 2021-09-30
CA3130406A1 (en) 2020-08-27
US20220071958A1 (en) 2022-03-10
MA55021A (fr) 2021-12-29
BR112021016153A2 (pt) 2021-10-05
EP4349407A2 (en) 2024-04-10
PT3927337T (pt) 2024-05-17
EP3927337B8 (en) 2024-03-20
KR20210154966A (ko) 2021-12-21
DOP2021000176A (es) 2021-11-21
PE20220015A1 (es) 2022-01-11
EA202192318A1 (ru) 2021-12-21
MA55021B1 (fr) 2024-05-31
EP3927337A1 (en) 2021-12-29
CO2021010882A2 (es) 2022-01-17
DK3927337T3 (da) 2024-04-22
JP2022521337A (ja) 2022-04-06
MX2021009941A (es) 2021-12-10
WO2020169850A1 (en) 2020-08-27
CN114555078A (zh) 2022-05-27
FI3927337T3 (fi) 2024-05-08
CL2021002174A1 (es) 2022-01-28
EP3927337B1 (en) 2024-02-14
AU2020225410A1 (en) 2021-08-19
EP4353314A2 (en) 2024-04-17
NI202100080A (es) 2021-12-06

Similar Documents

Publication Publication Date Title
DOP2021000176A (es) 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresión
CO2021010883A2 (es) Composiciones que comprenden 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para su uso en el tratamiento de trastornos mentales
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
CL2017003006A1 (es) Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t
NI201700137A (es) Derivados de indol mono o disustituidos como inhibidores de la replicaciã“n viral del dengue
AR054371A1 (es) Metodos y composiciones para manejo de desordenes psicoticos
UY28862A1 (es) Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii
EA201892657A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201691847A1 (ru) Способы снижения сердечно-сосудистого риска
CU20120034A7 (es) Compuestos y composiciones como inhibidores de cinasa de proteína
EA201990425A1 (ru) Спиролактамовые и бис-спиролактамовые модуляторы nmda-рецептора и их применение
EA033448B1 (ru) Композиция орлистата и акарбозы с модифицированным высвобождением для лечения ожирения и связанных метаболических нарушений
CO2022007814A2 (es) Ligandos de la pseudoquinasa tyk2
EA202092225A1 (ru) Соединения и их применение
CL2021001136A1 (es) Composiciones y métodos para tratar y prevenir la esclerosis lateral amiotrófica.
CO2022013429A2 (es) Formulaciones de liberación controlada que comprenden drotaverina o sal de la misma
EA201990976A1 (ru) Новый способ профилактического лечения непроизвольной потери массы
EA201990602A3 (ru) Комбинации пальмитоилэтаноламида для лечения хронической боли
CO2021005797A2 (es) Métodos y formulaciones para tratar náuseas y vómitos inducidos por quimioterapia
BR112018009476A8 (pt) regime de dosagem de plasminogênio para cicatrização de ferimentos
BR112018015483A2 (pt) formulações farmacêuticas sólidas estáveis que contêm 2-(2-nitro-4-trifluorometil-benzoil)-1,3 -ciclo-hexanodiona
AR116592A1 (es) Tratamiento de la colangitis biliar primaria y la colangitis esclerosante primaria con baricitinib
BR112020014583A8 (pt) Composição para tratar um paciente que sofre de colite ulcerosa e uso da composição como um fármaco
EA201892830A1 (ru) Применение ксиборнола в качестве активного агента для лечения вирусных инфекций
BR112018016651A2 (pt) composições e métodos para tratamento de doença e distúrbios de sinusite